The Penn Colton Center has launched two new Centers of Excellence — HIT-AI, focused on AI-driven drug repurposing, and CREATE, pioneering mRNA therapies — to accelerate next-generation autoimmune diagnostics and treatments.
A Colton-supported NYU study published in Science Translational Medicine has identified impaired regulatory T cells as a key driver of Sjögren's disease — and found a promising existing drug as a potential therapy.
Yale's Colton Center for Autoimmunity has selected eleven faculty-led projects for 2024 funding, supporting breakthrough research into lupus, asthma, allergies, and other autoimmune diseases — with mentorship and commercialization support included.
